Tumor radioresponsiveness versus fractionation sensitivity

Area of Science:

• Radiation Oncology
• Cancer Biology
• Radiobiology

Background:

• Traditional measures of radiation sensitivity (D0, N, Dq) are best suited for high-dose radiation.
• Clinical radiation therapy increasingly uses small fractional doses (1-2 Gy), necessitating new metrics for assessing tumor response.
• Existing radioresponsiveness measures may not accurately reflect outcomes with modern fractionation schedules.

Purpose of the Study:

• To introduce and validate a new quantitative measure of tumor radioresponsiveness, alpha/E, suitable for clinical fractional dose schedules.
• To establish alpha/E as a more relevant metric than traditional parameters for predicting tumor control in low-dose-per-fraction radiotherapy.
• To differentiate alpha/E from alpha/beta, a measure of fractionation sensitivity, and explore their relationship.

Main Methods:

• Derived the alpha/E ratio from the linear-quadratic model for cell inactivation, representing the intercept on a reciprocal-dose plot.
• Proposed alpha/E as the reciprocal of the TCD50 (tumor control dose for 50% of tumors) under specific low-dose-per-fraction or low-dose-rate conditions.
• Defined alpha as the initial slope of the dose-survival curve and E as the log of the surviving clonogens needed for tumor control.

Main Results:

• The alpha/E ratio is proposed as a measure of tumor radioresponsiveness applicable to clinical fractional doses (1-2 Gy).
• Alpha/E reflects the steepness of the initial cell-survival curve (alpha) and the required clonogen kill for tumor control (E).
• Literature review suggests alpha/E and alpha/beta (fractionation sensitivity) generally do not correlate, except in specific tumor types like hypoxic tumors.

Conclusions:

• The alpha/E ratio offers a more clinically relevant measure of tumor radioresponsiveness for modern radiotherapy fractionation schedules.
• This metric provides a better understanding of tumor response at the small doses per fraction commonly employed in clinical practice.
• Further research and data collection are needed to fully determine the alpha/E ratio across various tumor types and treatment conditions.